Results 161 to 170 of about 2,460,078 (269)

Knowledge, attitudes, and practices among guardians toward inherited retinal diseases: a structural equation modeling analysis. [PDF]

Sci Rep
Chen X, Ran Y, Wen N, Fan S, Wen M, Feng Z, Jiang J, Huang S.   +7 more
europepmc   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Using deep learning to identify inherited retinal diseases based on wide-field retinal imaging data. [PDF]

PLoS One
Joskowicz L, Buchbinder T, Chodorov E, Hoogi A, Matos K, Rivera A, Sharon D, Banin E, Levy J.   +8 more
europepmc   +1 more source

Monitoring pharmacodynamic and molecular drug targets in liquid biopsy: Exploratory study in liver cancer with modelling of EGFR Receptor engagement

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Liquid biopsy is minimally invasive (compared with tissue biopsy) and has previously been used to generate systems data regarding drug elimination via hepatic enzymes and transporters. This study extends quantitative assessment of systems parameters in liquid biopsy to pharmacodynamic (PD) and disease markers relevant to cancer development
Zubida M. Al‐Majdoub, Armin Sepp, Amin Rostami‐Hodjegan, Brahim Achour   +3 more
wiley   +1 more source

Mental health outcomes in patients with inherited retinal diseases: a systematic review and meta-analysis. [PDF]

Int J Retina Vitreous
Abu Serhan H, Ahmed A, Sbei O, Kojan W, Chaudhry M, Khalid M, Sheraz A, Al-Moujahed A.   +7 more
europepmc   +1 more source

Machine Learning Models of Phase Contrast Images Predict Efficiency of Human Pluripotent Stem Cell Differentiation to Cardiomyocytes

Biotechnology and Bioengineering, EarlyView.
Human pluripotent stem cells were differentiated to cTnT+ cardiomyocytes and imaged throughout the process using phase contrast. We predicted differentiation efficiency (cTnT+ area) from phase contrast and compared model performance with a live‐cell cTnT‐GFP reporter.
Austin K. Feeney, Yaniv Ovadia, Aaron D. Simmons, Christian Elabd, Claire J. Peplinski, Frank Li, Sean P. Palecek   +6 more
wiley   +1 more source

Real-World Comparison of Overall Survival Among Patients With and Without Inherited Retinal Diseases. [PDF]

Vision (Basel)
Lam BL, Mendoza-Santiesteban CE, Pilon D, Milentijevic D, Morrison L, Schwartzbein S, Vanden Eynde C, Lafeuille MH, Lefebvre P, Gregori NZ.   +9 more
europepmc   +1 more source

What Makes an “Ideal” Cell Line for Recombinant Adeno‐Associated Virus Production?

Biotechnology and Bioengineering, EarlyView.
Several host cell types have been used to produce rAAVs to date. Cell line‐specific traits that are beneficial in the context of rAAV manufacturing are reviewed here, with the goal of developing a consensus on the ‘ideal’ characteristics that an rAAV production host should possess (created with Biorender.com).
James Conheady, Nicholas Donohue, Alexandra Bogdanovic, Sharon Davin, Brian Glennon, Niall Barron, C. Mark Smales   +6 more
wiley   +1 more source

Stem cell-based therapies for inherited retinal diseases - Translational advances and clinical evidence: A review. [PDF]

Biomol Biomed
Huang Y, Xie Y, Wang C.
europepmc   +1 more source

Cell and Gene Therapies Manufacturing Challenges and Integrated Good Manufacturing Practices Solutions: A Lifecycle Perspective

Biotechnology and Bioengineering, EarlyView.
Lifecycle perspective on cell and gene therapy manufacturing challenges and enabling GMP solutions. ABSTRACT Cell and gene therapies (CGTs) are revolutionizing modern medicine; however, making these advanced medicines scalable and readily available to commercial manufacturers worldwide is a major challenge. The number of approved CGT products continues
Rajath Samaga, Udisha Singh, Sachin Dattram Pawar   +2 more
wiley   +1 more source